Symeres

Executive Summary

Symeres is a Netherlands-based transatlantic Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecules and drug delivery technologies. Founded in 2019, the company offers integrated drug discovery and development services spanning chemistry, biology, ADME-tox, and CMC, guiding clients from initial concept through IND filing. With a single accountable program lead model, Symeres aims to streamline the drug development process for pharmaceutical and biotech partners. As a private, pre-clinical stage company, Symeres has not disclosed funding or valuation details but operates in the competitive CRO/CDMO market. Its focus on integrated services and transatlantic presence positions it to capture demand from early-stage drug developers seeking efficient outsourcing solutions. The company's growth will depend on client acquisition, service expansion, and potential facility investments to differentiate from larger players.

Upcoming Catalysts (preview)

• Q4 2026Expansion of CDMO capacity or new facility announcement60% success
• H1 2027Major partnership or multi-year contract win with a top pharma40% success
• Q2 2027Launch of new drug delivery platform or technological enhancement50% success